While the ability of Myc-driven lymphoma cells to grow in the absence of Runx1 is surprising, their impaired proliferation and increased chemo-sensitivity validates Runx1 function as a candidate target in future combination therapies. The gene discussed is MYC; the disease is lymphoma.